Eledon Pharmaceuticals Inc. (ELDN): Price Target Chart
The following quotes for Eledon Pharmaceuticals (ELDN) demonstrate the dynamics of a company whose indicators reach 9.53. The business is vulnerable to component logistics disruptions and challenges with foreign patenting. Meanwhile, the enterprise is upgrading its filtration and purification equipment, maintaining its assets in pristine condition. The firm's resilience is supported by the development of agents against transplant rejection and successful trials of new immunological products.
Analytical breakdowns for Eledon (ELDN)
- current quotes and average value forecast:
- stock exchange capitalization data:
- issuer book value statistics:
- debt obligations and liquidity statistics:
Aggregate Debt to Equity Eledon Pharmaceuticals|ELDN - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Eledon Pharmaceuticals, Inc|ELDN - Company Aggregate Debts|Debts to Book Capitalization Eledon|ELDN - Company Long-Term Debt|Company Short-Term Loans and Borrowings Eledon Pharmaceuticals|Quick Liquidity Indicator eledon.com
- net income and valuation multiples indicators:
ELDN - Net Profit|Projected Future Earnings Eledon Pharmaceuticals|ELDN - Price to Earnings Ratio|Future Price to Earnings Multiple Eledon Pharmaceuticals Inc.|ELDN - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Eledon|ELDN - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Eledon Pharmaceuticals|ELDN - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months eledon.com|ELDN - Net earnings per share growth this year|Earnings growth forecast for next year Eledon Pharmaceuticals
General company analysis:ELDN eledon.com
When constructing a long-term portfolio, it is critical to align an asset's market value with its fundamental value. This analyst target consensus for Eledon Pharmaceuticals (ELDN) represents the weighted average of expert price expectations, reflecting the collective assessment of the company's prospects in immunology and the fight against transplant rejection, which allows this chart to track the dynamics of market confidence in the company's clinical trials.
Competitors of Eledon Pharmaceuticals
ARGX - Average Forecast Price|Price Target Chart BioNTech BNTX|Abivax SA - Price Target Chart|ADMA Bio - Analyst Consensus Forecast|PTGX (Protagonist Corp) - Broker Consensus Forecast|Immunovant, Inc. (IMVT) - Price Target Chart|Broker Consensus Forecast KNSA|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|Aerovate - Analyst Consensus Forecast|Average Forecast Price Aclaris Therapeutics, Inc|Kyverna Therapeutics (KYTX) - Price Target Chart|TLSA (tizianalifesciences.com) - Price Target Chart|CABA (Cabaletta Bio) - Analyst Consensus Forecast|Average Forecast Price Ventyx Biosciences Inc. VTYX|Analyst Consensus Forecast THTX|Avalo Therapeutics Inc - Broker Consensus Forecast|Price Target Chart Agenus AGEN|climbbio.com (CLYM) - Average Forecast Price|ZURA - Price Target Chart|ATYR (aTyr Pharma Inc) - Broker Consensus Forecast|ADAG (adagene.com) - Consensus Target|Ikena Oncology - Fair Value Consensus|Price Target Chart Shattuck Labs Inc|Equillium Bio - Forecast Levels Chart|Analyst Consensus Forecast CNTB|IMUX (immunic-therapeutics.com) - Fair Value Consensus|Analyst Consensus Forecast ATRA (Atara Bio)|Analyst Consensus Forecast InflaRx NV IFRX|XFOR - Price Target Chart|Fair Value Consensus ACET (Adicet Bio)|celularity.com (CELU) - Price Target Chart|Consensus Target INmune Bio Inc|BRNS (Barinthus Bio) - Analyst Consensus Forecast|Analyst Consensus Forecast Kezar Life Sciences Inc|Analyst Consensus Forecast SABS|Consensus Target akaritx.com AKTX|Analyst Consensus Forecast ENLV (Enlivex Therapeutics Ltd.)|Q32 Bio Inc (QTTB) - Average Forecast Price|GOVX: Consensus Target|EDSA - Analyst Consensus Forecast|IBIO (iBio, Inc.) - Consensus Target|CARM: Analyst Forecast Prices|XTLB (XTL Biopharmaceuticals Ltd.) - Analyst Consensus Forecast|Bolt Bio (BOLT) - Analyst Median Target|Analyst Consensus Forecast HCWB|Consensus Target aptevotherapeutics.com APVO|Analyst Consensus Forecast AIM (AIM ImmunoTech)|Analyst Consensus Forecast Aditxt Inc. ADTX|GRI - Price Target Chart|XRTX: Price Target Chart|ReShape Lifesciences (HIND) - Price Target Chart|REVB - Analyst Median Target|INDP (Indaptus Therapeutics) - Analyst Consensus Forecast|Average Forecast Price scinai.com SCNI|Price Target Chart CalciMedica, Inc. (CALI)|Price Target Chart AFMD (affimed.com)|Analyst Consensus Forecast ALLK (Allakos)|HOOK: Broker Consensus Forecast|IGMS - Price Target Chart|ITOS (iteostherapeutics.com) - Broker Consensus Forecast|Ocean Biomedical (OCEA) - Price Target Chart|Forecast Levels Chart TCBP (TC BioPharm (Holdings) Plc)|THRD (Third Harmonic Bio, Inc) - Analyst Consensus Forecast
